3-isopropoxy-phenyl isothiocyanate | 3528-90-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-isopropoxy-phenyl isothiocyanate
• 英文别名: 3-Isopropoxy-phenylisothiocyanat；3-isopropoxyphenyl isothiocyanate；1-isothiocyanato-3-propan-2-yloxybenzene
• CAS: 3528-90-3
• 化学式: C₁₀H₁₁NOS
• 分子量: 193.269
• InChiKey: SHEUTMKVKORWJF-UHFFFAOYSA-N

物化性质

• 沸点：
  98-100 °C(Press: 0.2 Torr)
• 密度：
  1.1593 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  53.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-isopropoxy-phenyl isothiocyanate 在 溶剂黄146 、 肼 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 50.0h， 生成 benzoic acid, 4-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-hydrazino]carbonyl]amino]-, ethyl ester
  参考文献：
  名称：

  Novel Nonpeptide CCK-B Antagonists:  Design and Development of Quinazolinone Derivatives as Potent, Selective, and Orally Active CCK-B Antagonists

  摘要：

  We have designed a novel series of CCK-B receptor antagonists by combining key pharmacophores, an arylurea moiety of 1 and a quinazolinone ring of 3, from two known series. Our earlier studies showed that compounds with methylene linkers in our "target" produced moderate binding affinity and selectivity for CCK-B receptors, whereas its higher and lower homologues resulted in loss of affinity. Introduction of -NH- as a linker dramatically enhanced binding affinity and selectivity for CCK-B receptors, thus providing several compounds with single-digit nanomolar binding affinity and excellent selectivity. Analogous to the earlier studies of the series of quinazolinone derivatives 3, we also found 3-isopropoxyphenyl as a preferred substitution on the N-3 quinazolinone. Electron-withdrawing substitutions on the urea terminal phenyl ring enhanced the CCK-B potency. Representative compounds of this series were tested in the functional assay and showed pure antagonist profiles. Compounds 51 and 61 were orally active in the elevated rat X-maze test. These compounds were also evaluated for their pharmacokinetic profile. The absolute oral bioavailability of compound 61 was 22% in rats.

  DOI：

  10.1021/jm970373j
• 作为产物：
  描述：

  硫光气 、 3-氨基苯异丙醚 在 三乙胺 作用下， 以 CHC₃ 、 乙酸乙酯 为溶剂， 生成 3-isopropoxy-phenyl isothiocyanate
  参考文献：
  名称：

  Quinazolinone derivatives as cholyecystokinin (CCK) ligands

  摘要：

  本发明涉及具有良好结合亲和力的新型喹唑啉衍生物，用于CCK-A和CCK-B受体，含有它们的药物组合物，使用它们的方法以及一种新型制备方法。这些化合物是用于抑制食欲、减少胃酸分泌等方面的有用药剂。

  公开号：

  US05756502A1

文献信息

• Substituted benzazoles and methods of their use as inhibitors of Raf kinase
  申请人：——

  公开号：US20040122237A1

  公开（公告）日：2004-06-24

  New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的替代苯唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新化合物组合物可以单独使用，也可以与至少一种额外药物结合，用于治疗由Raf激酶介导的疾病，如癌症。
• Heterocycles as cholecystokinin (CCK) ligands
  申请人：Padia Janak Khimchand

  公开号：US06897213B1

  公开（公告）日：2005-05-24

  Novel quinazolinone derivatives with good binding affinity for the CCK-A and CCK-B receptors, pharmaceutical compositions containing them and methods of using them are taught. The compounds are useful agents to suppress appetite, reduce gastric acid secretion, and the like.

  教授具有良好结合亲和力的新型喹唑啉衍生物对CCK-A和CCK-B受体，含有它们的药物组合物以及使用它们的方法。这些化合物是用于抑制食欲、减少胃酸分泌等的有用药剂。
• Quinazolinone derivatives as cholecystokinin (CCK) ligands
  申请人：Warner-Lambert Company

  公开号：US05869665A1

  公开（公告）日：1999-02-09

  Novel quinazolinone derivatives with good binding affinity for the CCK-A and CCK-B receptors, pharmaceutical compositions containing them, methods of using them and a novel process for their preparation are taught. The compounds are useful agents to suppress appetite, reduce gastric acid secretion, and the like.

  本发明涉及新型喹唑啉衍生物，其对CCK-A和CCK-B受体具有良好的结合亲和力，以及含有它们的制药组合物、使用它们的方法和一种新型制备它们的方法。这些化合物是有用的药剂，用于抑制食欲、减少胃酸分泌等。
• SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE
  申请人：Amiri Payman

  公开号：US20120288501A1

  公开（公告）日：2012-11-15

  New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的取代苯唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新的化合物组合物可以单独使用或与至少一种额外的药物联合使用，用于治疗Raf激酶介导的疾病，如癌症。
• WO2006/64189
  申请人：——

  公开号：——

  公开（公告）日：——